Strategy

Merck bolsters vaccine making division with the addition of 400 new employees to fill its new manufacturing plant.

French drugmaker to cut 800 jobs, joining the long list of companies restructuring to make ends meet.

Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.

In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates

How do you find and license the best drugs out there? If you're Merck, you send scientists to go get 'em

Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work

Meet the Korean pharma consumer: affluent, aging, and crazy about drugs

San Diego's booming biotech cluster searches for its future-and yours

Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging.

Bill Gates and Co. officially released Office for Business Applications (OBA) for the life sciences industry. This set of tools allows software developers to build applications that seamlessly connect back-end enterprise systems with MS Office programs.

With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

Here's the saga of how market research, health outcomes, and dozens of other tools that connect the industry to patients came to be.

...and other ways you never thought to sell your drugs

The contamination of heparin in China cast the drugmaker, its US supplier, and FDA as indifferent and incompetent. Then the story took a very strange turn...

A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

A review of a pilot ePrescribing program reveals that if physicians are given the proper support, the technology can increase safer prescribing habits and boost compliance.

Roche has always gone its own way with biologics, deals, and new medicines. Now that the rest of industry has caught on, how can Roche stay ahead of its time?

A new study shows that while doctors aren't in a rush to stop prescribing Vytorin, they are considering it less often as a first-line treatment option.

US officials think they can control MRSA and other "superbugs," but dangerous bacteria know no boundaries. What does the world do when its drugs stop working?

In the wake of the ENHANCE study, new prescriptions of the cholesterol-lowering drug Vytorin are dropping drastically, but calls to sales reps by physicians are on the rise.

Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.